Ondine Biomedical Inc. OBIMF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 449.70K | 453.80K | 585.70K | 592.80K | 366.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 449.70K | 453.80K | 585.70K | 592.80K | 366.10K |
| Cost of Revenue | 156.80K | 158.20K | 243.20K | 246.10K | 128.70K |
| Gross Profit | 293.00K | 295.60K | 342.50K | 346.70K | 237.40K |
| SG&A Expenses | 1.80M | 1.82M | 1.76M | 1.78M | 1.78M |
| Depreciation & Amortization | 91.00K | 91.90K | 86.10K | 87.10K | 101.90K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.20M | 6.26M | 6.84M | 6.93M | 4.89M |
| Operating Income | -5.75M | -5.80M | -6.26M | -6.33M | -4.52M |
| Income Before Tax | -5.84M | -5.89M | -6.08M | -6.16M | -4.54M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.84M | -5.89M | -6.08M | -6.16M | -4.54M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.84M | -5.89M | -6.08M | -6.16M | -4.54M |
| EBIT | -5.75M | -5.80M | -6.26M | -6.33M | -4.52M |
| EBITDA | -5.70M | -5.75M | -6.21M | -6.27M | -4.48M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 532.30M | 532.30M | 492.92M | 492.92M | 437.24M |
| Average Diluted Shares Outstanding | 532.30M | 532.30M | 492.92M | 492.92M | 437.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |